Author
Listed:
- Nourhan Abdelfattah
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio
Faculty of Science, Cairo University)
- Subapriya Rajamanickam
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
- Subbarayalu Panneerdoss
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
- Santosh Timilsina
(University of Texas Health Science Center at San Antonio)
- Pooja Yadav
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
- Benjamin C. Onyeagucha
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
- Michael Garcia
(University of Texas Health Science Center at San Antonio)
- Ratna Vadlamudi
(University of Texas Health Science Center at San Antonio)
- Yidong Chen
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
- Andrew Brenner
(University of Texas Health Science Center at San Antonio)
- Peter Houghton
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
- Manjeet K. Rao
(University of Texas Health Science Center at San Antonio
University of Texas Health Science Center at San Antonio)
Abstract
Despite improvements in overall survival, only a modest percentage of patients survives high-risk medulloblastoma. The devastating side effects of radiation and chemotherapy substantially reduce quality of life for surviving patients. Here, using genomic screens, we identified miR-584-5p as a potent therapeutic adjuvant that potentiates medulloblastoma to radiation and vincristine. MiR-584-5p inhibited medulloblastoma growth and prolonged survival of mice in pre-clinical tumor models. MiR-584-5p overexpression caused cell cycle arrest, DNA damage, and spindle defects in medulloblastoma cells. MiR-584-5p mediated its tumor suppressor and therapy-sensitizing effects by targeting HDAC1 and eIF4E3. MiR-584-5p overexpression or HDAC1/eIF4E3 silencing inhibited medulloblastoma stem cell self-renewal without affecting neural stem cell growth. In medulloblastoma patients, reduced expression of miR-584-5p correlated with increased levels of HDAC1/eIF4E3. These findings identify a previously undefined role for miR-584-5p/HDAC1/eIF4E3 in regulating DNA repair, microtubule dynamics, and stemness in medulloblastoma and set the stage for a new way to treat medulloblastoma using miR-584-5p.
Suggested Citation
Nourhan Abdelfattah & Subapriya Rajamanickam & Subbarayalu Panneerdoss & Santosh Timilsina & Pooja Yadav & Benjamin C. Onyeagucha & Michael Garcia & Ratna Vadlamudi & Yidong Chen & Andrew Brenner & Pe, 2018.
"MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma,"
Nature Communications, Nature, vol. 9(1), pages 1-19, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06808-8
DOI: 10.1038/s41467-018-06808-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06808-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.